Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1b Clinical Study to Investigate the Safety and Immunogenicity of the Bris10 (A/Brisbane/10/2007) M2SR and Sing2016 (A/Singapore/INFIMH-16-0019/2016) M2SR H3N2 Monovalent Influenza Vaccines

NCT03999554 is registered in ClinicalTrials.gov with FluGen Inc as lead sponsor.

NCT NCT03999554
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03999554 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1b Clinical Study to Investigate the Safety and Immunogenicity of the Bris10 (A/Brisbane/10/2007) M2SR and Sing2016 (A/Singapore/INFIMH-16-0019/2016) M2SR H3N2 Monovalent Influenza Vaccines
Lead sponsor
FluGen Inc
Phase
Phase 1
Overall status
Completed
Start date
September 3, 2019
Completion date
July 1, 2020
Enrollment
206 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

influenza a